Kimura, Hiroko http://orcid.org/0000-0001-8071-6700
Mizuno, Kei
Shiota, Masaki
Narita, Shintaro
Terada, Naoki
Fujimoto, Naohiro
Ogura, Keiji
Hatano, Shotaro
Iwasaki, Yusuke
Hakozaki, Nozomi
Ishitoya, Satoshi
Sumiyoshi, Takayuki
Goto, Takayuki
Kobayashi, Takashi http://orcid.org/0000-0003-1069-2816
Nakagawa, Hidewaki
Kamoto, Toshiyuki
Eto, Masatoshi
Habuchi, Tomonori
Ogawa, Osamu
Momozawa, Yukihide
Akamatsu, Shusuke http://orcid.org/0000-0002-1394-7506
Funding for this research was provided by:
MEXT | Japan Society for the Promotion of Science (20H03814)
Article History
Received: 31 December 2021
Revised: 8 July 2022
Accepted: 8 July 2022
First Online: 19 August 2022
Competing interests
: SA received research funding from Astellas Pharma, AstraZeneca, and Tosoh, outside of the submitted work and honoraria from Janssen Pharmaceutical, AstraZeneca, Astellas Pharma, Sanofi, Bayer and Takeda Pharmaceutical. MS received research funding from Daiichi Sankyo Company and honoraria from Janssen Pharmaceutical, AstraZeneca and Astellas Pharma. SN received honoraria from Janssen Pharmaceutical, Bayer, AstraZeneca, Takeda Pharmaceutical, Sanofi, Nippon Shinyaku and Astellas Pharma. NF received funding from Takeda Pharmaceutical and Sanofi and honoraria from Janssen Pharmaceutical, Takeda Pharmaceutical, Astellas Pharma and Nippon Shinyaku. T Kobayashi received funding from AstraZeneca and Chugai Pharmaceutical and honoraria from Janssen Pharma, AstraZeneca, Chugai Pharmaceutical, Bayer, MSD, Sanofi, Takeda, Astellas, Nippon Shinyaku, Nihon Kayaku, Merck and Pfizer. ME received research funding from Sanofi, Bayers, Astellas Pharma, Ono Pharmaceutical and Takeda Pharmaceutical and honoraria from Ono Pharmaceutical, Takeda Pharmaceutical, Novartis, Pfizer, Bristol Myers Squibb, Janssen Pharmaceutical, MSD and Merck. TH received research funding from Takeda Pharmaceutical, Astellas Pharma, Daiichi Sankyo Company, Sanofi and Bayer and honoraria from Janssen Pharmaceutical, Takeda Pharmaceutical, Astellas Pharma, Daiichi Sankyo Company, AstraZeneca, Sanofi and Bayer. OO received research funding from Shimazu, Astellas Pharma, and Chugai Pharmaceutical and honoraria from Sanofi, Nihon Kayaku, MSD, Bayer, Daiichi Sankyo Company, Ono Pharmaceutical, Nippon Shinyaku and Takeda Pharmaceutical.
: The study, which was conducted in accordance with the Declaration of Helsinki, was approved by the ethics committees of RIKEN, Akita University, Kyusyu University, University of Occupational and Environmental Health, Miyazaki University, Kyoto University (approval number G1154), and the Japanese Red Cross Otsu Hospital. All participants at Akita University, Kyusyu University, University of Occupational and Environmental Health, Miyazaki University, and Kyoto University provided written informed consent for the genomic analysis of their blood samples. Regarding the archived biopsy samples obtained from patients at the Japanese Red Cross Otsu Hospital, even though the patients provided informed consent for the use of their material, genomic analysis was not specified in the consent form. Therefore, to prevent patient re-identification, under the guidance of the ethics committee of Kyoto University, all biopsy samples and clinical data were completely anonymized before the study was conducted.
: Not applicable.